Safety assessment of Streptococcus salivarius DB-B5 as a probiotic candidate for oral health.

Autor: Li X; Dose Biosystems Inc., 661 University Ave., Suite 1300, Toronto, ON, M5G 0B7, Canada., Fields FR; Dose Biosystems Inc., 661 University Ave., Suite 1300, Toronto, ON, M5G 0B7, Canada., Ho M; Dose Biosystems Inc., 661 University Ave., Suite 1300, Toronto, ON, M5G 0B7, Canada., Marshall-Hudson A; TKL Research, Inc., One Promenade Boulevard, Suite 1201, Fair Lawn, NJ, 07410, USA., Gross R; TKL Research, Inc., One Promenade Boulevard, Suite 1201, Fair Lawn, NJ, 07410, USA., Casser ME; TKL Research, Inc., One Promenade Boulevard, Suite 1201, Fair Lawn, NJ, 07410, USA., Naito M; Dose Biosystems Inc., 661 University Ave., Suite 1300, Toronto, ON, M5G 0B7, Canada. Electronic address: mizue@dosebiosystems.com.
Jazyk: angličtina
Zdroj: Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association [Food Chem Toxicol] 2021 Jul; Vol. 153, pp. 112277. Date of Electronic Publication: 2021 May 15.
DOI: 10.1016/j.fct.2021.112277
Abstrakt: Streptococcus salivarius DB-B5 was previously isolated from the supragingival plaque of a healthy female adult and selected for development as a probiotic candidate for oral health. Probiotics are an important emerging therapeutic method for preventing, treating, and maintaining oral health. Although S. salivarius is a predominant member of the commensal oral microbiota and generally regarded as a safe species, it is recognized that each strain needs to be comprehensively assessed for safety. This study describes the in silico, in vitro, and clinical testing that were conducted to evaluate the safety of S. salivarius DB-B5. Both 16S rRNA and multi-gene phylogenetic reconstruction was used to confirm the taxonomic identity of this strain. Bioinformatic analysis of the genome demonstrated the absence of transmissible antibiotic resistance genes or virulence factors. Phenotypic testing further showed S. salivarius DB-B5 to be susceptible to clinically relevant antibiotics. S. salivarius DB-B5 displayed weak alpha-hemolysis, and does not produce biogenic amines. In a randomized, double-blind, placebo-controlled clinical study, consumption of S. salivarius DB-B5 at 10 billion CFU/day for 4 weeks by healthy adults was safe and well-tolerated (ClinicalTrials.gov registry number NCT04492631). This work has indicated that S. salivarius DB-B5 is a safe probiotic candidate.
(Copyright © 2021 Dose Biosystems Inc. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: